DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1. In vivo evaluation of morphine and oxycodone either alone or in combination or as prodrugs MLN 2-31 and MLN 2-45 in CD1 mice. Patent Application Publication Oct. 6, 2011 Sheet 2 of 3 US 2011/0245287 A1 I.C.W. antinociception of morphine and the bivalent ligands in CD lice --Morphine ('pt - i.c. v.) -- MLN II - 83 (20 pt- i.c...) s s () 1000 10000 prolimouse Figure 2. In vivo evaluation of morphine or hybrid opioid compounds MLN 2-83, MLN 2 120 and MLN 2-121 in CD1 mice. Patent Application Publication Oct. 6, 2011 Sheet 3 of 3 US 2011/0245287 A1 L (1) Figure 3. US 2011/0245287 A1 Oct. 6, 2011 HYBRD OPOD COMPOUNDS AND ids and potentially toxic opioid metabolites (Smith, Clin. Exp. COMPOSITIONS Pharmacol. Physiol. 2000, 27, 524-528: Ross et al., Pain, 1997, 73, 151-157). 0010. The opioid receptor is thought to have four receptor 0001. This application claims priority to provisional appli Subtypes named mu (morphine receptor), sigma (the phen cation Ser. No. 61/302,657, filed Feb. 9, 2010, the entirety of cyclidine receptor), kappa (the ketocyclazocine receptor) and which is incorporated herein by reference. delta (the endorphin?enkephalin receptor). The biochemical and cellular effects of morphine, including analgesia, are BACKGROUND transduced through the mu opioid receptor (MOR), found in 0002 1. Technical Field high concentrations within the central nervous system (CNS). 0003. This invention is directed to hybrid opioid com The World Health Organization's guidelines for the manage pounds, mixed opioid salts, and compositions comprising the ment of chronic cancer pain recommend that clinicians hybrid opioid compounds and mixed opioid salts. Methods of reserve strong opioids Such as oxycodone and morphine for use comprising administering an effective amount of the the relief of moderate to severe cancer pain (World Health hybrid opioid compounds or mixed opioid salts to treat Organization, 1986) and that two strong opioids should not be humans Suffering from pain are also provided. co-administered, presumably because it is generally thought 0004 2. Description of Related Art that all opioids exert their analgesic effects through the same 0005 Opioid compounds remain key agents for the treat receptor mechanisms in the central nervous system. However, ment of a wide variety of acute and chronic pain. The World recent studies by Maree Smith and co-workers have shown Health Organization has recommended morphine as the anal that the antinociceptive effects of structurally related oxyc gesic of choice for the treatment of severe cancer pain. Addi odone and morphine are differentially antagonized by nor tionally, morphine and related opioids are widely used to BNI (a K-selective opioid antagonist) and naloxonazine (se alleviate moderate to severe pain after Surgery or trauma, or lective -opioid receptor antagonist), indicating that they associated with medical illness Such as heart attack. Patients produce antinociception through different opioid receptor with apparently similar pain states have large differences in mechanisms (see Ross et al., Pain 1997, 73, 151-157). Fur opioid dosing requirements. Factors that contribute to this thermore, it has been found that co-administration of Sub variability include psychosocial status, type of pain (nocice antinociceptive doses of oxycodone with morphine to rats ptive, inflammatory, neuropathic or mixed) and its severity, resulted in Synergistic levels of antinociception (Ross et al., concurrent medications, gender and other genetic aspects, Pain 2000, 84, 421-428). Importantly, it was found that ani and whether patients are opioid-naive or tolerant. mals that received the Sub-antinociceptive doses of oxyc 0006 Unfortunately, the effects produced by morphine odone and morphine were similar to control animals with and similar opioid compounds make them amenable to abuse respect to CNS side effects. Administration of equipotent and are associated with many undesirable side effects, all doses of either opioid alone resulted in sedation of the rats. mediated through activation of the mu (MOR) and other This may suggest that co-administration of Sub-analgesic opioid receptors. They include physical and psychological doses of oxycodone and morphine to patients may provide dependence leading to addiction and other diverse patho synergistic antinociceptive relief with a reduction of CNS physiological states. Other undesirable side effects associ related side effects. ated with the use of opioids include postoperative nausea and 0011. One of the most challenging aspects of the treatment Vomiting, drowsiness, respiratory depression and gastrointes of infectious disease is the development of drug-resistant tinal and bladder dysfunction. strains of the infectious agent. Disease-causing microbes that 0007. In addition to the adverse physiological effects have become resistant to drug therapy are an increasing pub listed above, a major associated risk is that repeated daily lic health problem. Tuberculosis, gonorrhea, malaria, and administrations of morphine or morphine-like opioids will childhood ear infections are just a few of the diseases that eventually induce significant tolerance to the therapeutic have become hard to treat with antibiotic drugs. The wide effects of the drug as well as initiating some degree of physi spread development of multi-drug resistant forms of malaria cal dependence. Opioid tolerance is a phenomenon whereby in Africa and South East Asia is one such troubling phenom chronic exposure to a drug diminishes its antinociceptive or enon. The protozoal parasite responsible, plasmodium falci analgesic effect, or creates the need for a higher dose to parum, has gained resistance to most forms of monotherapy, maintain its effect. including chloroquine, a cheap and effective antimalarial 0008. The degree of tolerance and physical dependence drug that has been used for more than 40 years. vary with the particular opioid employed, the correlation with 0012. The scientific community has been actively devel morphine opioid receptor-selective opioids such as morphine oping new drugs to combat the increasingly drug-resistant being high, the frequency of administration, and the quantity strains of these and other infectious agents. One interesting of opioid administered. approach to fight drug-resistant strains is the development of 0009. In a wide variety of clinical indications requiring hybrid drugs that combine active agents with independent prolonged use of opioids, tolerance induction and addiction modes of action. Using this strategy, new active agents have are closely linked, with the development of physical and been prepared that show much promise for the treatment of psychological dependence always a major concern. Addic resistant microbes. For example, Walsh and co-workers pre tion with physical dependence can be difficult to treat due to pared novel hybrid molecules comprising active components the effects of withdrawal associated with dependence. of the drugs artemisinin and quinine. Walsh et al., Bioorg. Another undesirable effect of opioid tolerance is that the Med. Chem. Lett., 2007, 17(13),3599. The hybrid drugs were higher opioid requirements of highly tolerant patients treated reported to have potent activity against 3D7 (drug resistant) for pain increase the likelihood of unpleasant non-analgesic and FcB1 strains of Plasmodium falciparum in culture. The side effects due to greater circulating concentrations of opio activity was found to be Superior to artemisinin and quinine US 2011/0245287 A1 Oct. 6, 2011 alone. Dechy-Cabaret et al., (Chembiochem, 2000, No. 4, morphine, alvimopan, benzomorphans, buprenorphine, 281-283) reported the preparation of a novel trioxaquine mol codeine, 6-desomorphine, dihydromorphine, dihydromor ecules that contain that combine the peroxide entity
Load more

Recommended publications
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • Implications in the Management of Depression and Anxiety
    Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Year: 2016 Volume: 12 Neuropsychiatric Disease and Treatment Dovepress Running head verso: Montoya et al Running head recto: Noradrenergic paradox in depression and anxiety open access to scientific and medical research DOI: http://dx.doi.org/10.2147/NDT.S91311 Open Access Full Text Article REVIEW The noradrenergic paradox: implications in the management of depression and anxiety Alonso Montoya1 Abstract: Both major depressive disorder and the anxiety disorders are major causes of disability Robert Bruins1 and markedly contribute to a significant global burden of the disease worldwide. In part because Martin A Katzman2 of the significant socioeconomic burden associated with these disorders, theories have been devel- Pierre Blier3 oped to specifically build clinical treatment approaches. One such theory, the monoaminergic hypothesis, has led to the development of several generations of selective and nonselective inhibi- 1Eli Lilly Canada Inc, 2START Clinic for the Mood and Anxiety Disorders, tors of transporters of serotonin and norepinephrine, with the goal of augmenting monoaminergic Toronto, 3Mood Disorders Research transmission. These efforts have led to considerable success in the development of antidepressant Unit, Institute of Mental Health therapeutics. However, there is a strong correlation between enhanced noradrenergic activity Research, University of Ottawa, Ottawa, ON, Canada and fear and anxiety. Consequently, some physicians have expressed concerns that the same enhanced noradrenergic activity that alleviates depression could also promote anxiety. The fact that the serotonergic and noradrenergic reuptake inhibitors are successfully used in the treatment For personal use only. of anxiety and panic disorders seems paradoxical. This review was undertaken to determine if any clinical evidence exists to show that serotonergic and noradrenergic reuptake inhibitors can cause anxiety.
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Peripheral Kappa Opioid Receptor Activation Drives Cold Hypersensitivity in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice Manish K. Madasu1,2,3, Loc V. Thang1,2,3, Priyanka Chilukuri1,3, Sree Palanisamy1,2, Joel S. Arackal1,2, Tayler D. Sheahan3,4, Audra M. Foshage3, Richard A. Houghten6, Jay P. McLaughlin5.6, Jordan G. McCall1,2,3, Ream Al-Hasani1,2,3 1Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St. Louis, MO, USA. 2Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA 3Department of Anesthesiology, Pain Center, Washington University. St. Louis, MO, USA. 4 Division of Biology and Biomedical Science, Washington University in St. Louis, MO, USA 5Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA 6Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, USA Corresponding Author: Dr. Ream Al-Hasani Center for Clinical Pharmacology St. Louis College of Pharmacy Washington University School of Medicine 660 South Euclid Campus Box 8054 St. Louis MO, 63110 [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • 204760Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204760Orig1s000 OTHER REVIEW(S) MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: September 16, 2014 FROM: Julie Beitz, MD SUBJECT: Approval Action TO: NDA 204760 Movantik (naloxegol) tablets AstraZeneca Pharmaceuticals LP Summary Naloxegol is an antagonist of opioid binding at the muͲopioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherallyͲacting opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone and a new molecular entity. Pegylation confers the following properties: naloxegol has reduced passive permeability across membranes compared to naloxone; naloxegol is a PͲglycoprotein (PͲgp) efflux transporter substrate; and naloxegol is orally bioavailable. The reduced passive permeability and PͲgp efflux transporter properties limit CNS entry of naloxegol compared to naloxone. This memo documents my concurrence with the Division of Gastroenterology and Inborn Errors Product’s recommendation for approval of NDA 204760 for Movantik (naloxegol) tablets for the treatment of opioidͲinduced constipation (OIC) in adult patients with chronic nonͲcancer pain. Discussions regarding product labeling, and postmarketing study requirements and commitments have been satisfactorily completed. There are no inspectional issues that preclude approval. Dosing The recommended dose of Movantik (naloxegol) tablets is 25 mg taken once daily in the morning on an empty stomach. Patients who do not tolerate this dose, may reduce the dose to 12.5 mg once daily. Maintenance laxatives should be discontinued prior to initiation of therapy with Movantik.
    [Show full text]
  • Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn
    Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20100227876A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0227876 A1 Rech (43) Pub. Date: Sep. 9, 2010 (54) METHODS OF REDUCING SIDE EFFECTS Publication Classi?cation OF ANALGESICS (51) Int CL A61K 31/485 (2006.01) A61K 31/40 (2006.01) (75) Inventor: Richard H. Rech, Okemos, MI A61K 31/445 (2006-01) (Us) A61K 31/439 (2006.01) (52) US. Cl. ........................ .. 514/282; 514/409; 514/329 (57) ABSTRACT Correspondence Address: The invention provides for compositions and methods of MARSHALL, GERSTEIN & BORUN LLP reducing pain in a subject by administering a combination of 233 SOUTH WACKER DRIVE, 6300 WILLIS mu-opioid receptor agonist, kappal-opioid receptor agonist TOWER and a nonselective opioid receptor antagonist in amounts CHICAGO, IL 60606-6357 (US) effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The inven tion also provides for methods of enhancing an analgesic effect of treatment With an opioid-receptor agonist in a sub (73) Assignee: RECHFENSEN LLP, RidgeWood, ject suffering from pain While reducing an adverse side effect NJ (US) of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment With an opioid receptor agonist in a subject suffering from pain While reduc ing an adverse side effect of the treatment. The invention (21) Appl. No.: 12/399,629 further provides for methods of promoting the additive anal gesia of pain treatment With an opioid-receptor agonist in a subject in need While reducing an adverse side effect of the (22) Filed: Mar.
    [Show full text]
  • Opioids in Palliative Care: Evidence Update May 2014
    Opioids in palliative care Evidence Update May 2014 A summary of selected new evidence relevant to NICE clinical guideline 140 ‘Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults’ (2012) Evidence Update 58 Contents Introduction ................................................................................................................................ 3 Key points .................................................................................................................................. 4 1 Commentary on new evidence .......................................................................................... 5 1.1 Communication .......................................................................................................... 5 1.2 Starting strong opioids – titrating the dose ................................................................ 5 1.3 First-line maintenance treatment ............................................................................... 6 1.4 First-line treatment if oral opioids are not suitable – transdermal patches ................ 6 1.5 First-line treatment if oral opioids are not suitable – subcutaneous delivery ............. 7 1.6 First-line treatment for breakthrough pain in patients who can take oral opioids ...... 7 1.7 Management of constipation ..................................................................................... 8 1.8 Management of nausea ..........................................................................................
    [Show full text]
  • Axsome Therapeutics Enters Into Exclusive License Agreement with Pfizer Inc
    Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia Esreboxetine met primary endpoints in completed Pfizer Phase 3 and Phase 2 placebo-controlled clinical trials in fibromyalgia (p<0.001, and p<0.001) Pfizer to receive $11 million in Axsome stock and upfront cash, and up to $323 million in regulatory and sales milestones Company to host conference call today at 8:30 AM ET NEW YORK, January 13, 2020 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical- stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into an agreement with Pfizer Inc. (NYSE: PFE) for an exclusive U.S. license to Pfizer’s clinical and nonclinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which Axsome is developing for the treatment of narcolepsy. The agreement also provides Axsome exclusive rights to develop and commercialize esreboxetine, a new late-stage product candidate now referred to as AXS-14, in the U.S. for the treatment of fibromyalgia. Under the terms of the agreement, Axsome will receive from Pfizer an exclusive U.S. license to Pfizer data for reboxetine and esreboxetine encompassing a full range of nonclinical studies, and short-term and long-term clinical trials involving more than five thousand patients. The licensed data includes results from a positive Phase 3 and a positive Phase 2 trial of esreboxetine in the treatment of fibromyalgia.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]